7th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference

3rd - 4th February, 2022 | San Diego
Sponsors
Gold

Owlstone Medical

Owlstone Medical

Owlstone Medical’s mission is to save 100,000 lives and $1.5 billion in healthcare costs by realizing the potential of breath biomarkers for early detection and precision medicine through Breath Biopsy®. Breath Biopsy provides reliable solutions for the collection and analysis of volatile organic compounds (VOCs) produced through metabolic processes or as a result of interaction with external factors such as diet or medication. Changes to exhaled VOCs can be associated with a range of disease conditions and environmental exposures.

 


HTG Molecular Diagnostics, Inc.

HTG Molecular Diagnostics, Inc.

Headquartered in Tucson, Arizona, HTG is focused on accelerating precision medicine – from diagnosis to treatment – by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.  HTG’s proprietary extraction-free RNA expression technology simplifies and automates complex, highly multiplexed gene expression profiling from solid and (biofluid) liquid samples, even when limited by amount and quality. HTG’s transcriptome and targeted panels are designed to enable biomarker profile assessment and gene signature development associated with disease state, treatment response and outcome.


Proteome Sciences

Proteome Sciences

We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry.  By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.

With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.

Sponsors & Exhibitors

Rules-Based Medicine

Rules-Based Medicine

Rules-Based Medicine (RBM), a Q2 Solutions Company, is a CLIA certified, multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services and a novel whole blood immunophenotyping device (TruCulture®). RBM’s internally developed and manufactured immunoassays based on Multi-Analyte Profiling (MAP) and Single-Molecule Array (SimoaTM) ultrasensitive immunoassay technology provides translational and clinical researchers with reproducible and quantitative data for a few or hundreds of human proteins.  The comprehensive menu provides extensive coverage of numerous pathways and delivers accurate pharmacodynamic and safety assessments.  RBM’s CLIA certified biomarker testing laboratory is located in Austin, TX. 

Speaking Partner

QIAGEN

QIAGEN

Every day, QIAGEN serves 500,000 customers globally, all seeking insights from DNA and RNA. Delivering Sample to Insight solutions for molecular testing, we help scientists and clinicians achieve breakthroughs in life sciences research, molecular diagnostics and drug development. This is how we make improvements in life possible. In healthcare and academic institutions, and drug-discovery and forensic laboratories, QIAGEN solutions advance disease detection and treatments, enable precision medicine, and aid crime detection and human identification.


Biodesix

Biodesix

Biodesix® is an experienced blood-based diagnostic solutions company with a clinical focus in lung cancer. Our comprehensive diagnostic testing capabilities help our partners decipher the complexity of cancer by profiling both the tumor and immune system. Biodesix creates end-to-end solutions with our biopharma partners from initial biomarker discovery  to companion diagnostic partnering, including commercialization and reimbursement.